American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Apr 17, 2023
View PresentationAmerican Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Apr 17, 2023
View PresentationOppenheimer 33rd Annual Healthcare Conference
March 15, 2023
Read MoreAmerican Association for Cancer Research (AACR) Special Conference: Targeting RAS
Mar 7, 2023
View Presentation34th EORTC-NCI-AACR Symposium
Oct 27, 2022
View PresentationSporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 17, 2023
Read MoreSporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Mar 15, 2023
Read MoreSporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference
Mar 9, 2023
Read MoreFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
Oct 27, 2022
Read MoreSporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium
Oct 27, 2022
Read MoreTvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis
May 26, 2022
Read MoreTvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma
Apr 21, 2022
Read MoreData Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research
Apr 11, 2022
Read MoreNirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer
Jan 12, 2022
Read MoreSporos Bioventures Announces Formation of Strategic Advisory Board
Jan 11, 2022
Read MoreSporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors
Jan 4, 2022
Read MoreSporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer
Sep 19, 2021
Read MoreTvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
Jun 24, 2021
Read MoreStellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing
Jun 3, 2021
Read MoreAsylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
May 25, 2021
Read MoreSporos Launches with $38.1 Million Series A Financing
May 6, 2021
Read MoreNirogy Therapeutics to Present at AACR Annual Meeting 2021
Apr 7, 2021
Read MoreJLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System
Feb 17, 2021
Read MoreNirogy Therapeutics Launches with $16.5 Million Series A Financing
Jan 26, 2021
Read MoreTvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum
Dec 28, 2020
Read MoreNew Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement
Oct 9, 2020
Read MoreTvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers
Oct 4, 2020
Read MoreTvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research
Jun 24, 2020
Read MoreAsylia Therapeutics Moves into JLABS @TMC
Jun 6, 2020
Read MoreKRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences
Jun 3, 2020
Read MoreCPRIT Awards $3 Million to Asylia Therapeutics
May 11, 2020
Read MoreHeat Shock Protein-70 (HSP70) is an Essential Component of Anti-Tumor Immunity
May 2, 2020
Read MoreBiotech on the Rise
Jan 2, 2019
Read More